bit.bio has partnered with German biotechnology company myriamed to offer cryopreserved human induced pluripotent stem cell (iPSC)-derived cardiomyocytes for drug discovery and safety testing. The partnership gives researchers access to ventricular and atrial cardiomyocytes, alongside a dilated cardiomyopathy disease model and reporter cardiac cells for phenotypic screening. The cells will also be available through bit.bio’s […]
The post bit.bio expands human heart cell portfolio through myriamed partnership appeared first on Pharmafile.